TWI834720B - 可釋放glp-1共軛物 - Google Patents

可釋放glp-1共軛物 Download PDF

Info

Publication number
TWI834720B
TWI834720B TW108133127A TW108133127A TWI834720B TW I834720 B TWI834720 B TW I834720B TW 108133127 A TW108133127 A TW 108133127A TW 108133127 A TW108133127 A TW 108133127A TW I834720 B TWI834720 B TW I834720B
Authority
TW
Taiwan
Prior art keywords
compound
formula
group
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW108133127A
Other languages
English (en)
Chinese (zh)
Other versions
TW202034947A (zh
Inventor
馬瑞克 克維特瓦斯基
克里斯汀 桑德
Original Assignee
瑞典商奎亞培格製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商奎亞培格製藥公司 filed Critical 瑞典商奎亞培格製藥公司
Publication of TW202034947A publication Critical patent/TW202034947A/zh
Application granted granted Critical
Publication of TWI834720B publication Critical patent/TWI834720B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
TW108133127A 2018-09-12 2019-09-12 可釋放glp-1共軛物 TWI834720B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862730341P 2018-09-12 2018-09-12
US62/730,341 2018-09-12
US201862730935P 2018-09-13 2018-09-13
US62/730,935 2018-09-13
US201862771972P 2018-11-27 2018-11-27
US62/771,972 2018-11-27

Publications (2)

Publication Number Publication Date
TW202034947A TW202034947A (zh) 2020-10-01
TWI834720B true TWI834720B (zh) 2024-03-11

Family

ID=68382464

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108133127A TWI834720B (zh) 2018-09-12 2019-09-12 可釋放glp-1共軛物

Country Status (10)

Country Link
US (3) US11357828B2 (enExample)
EP (1) EP3849660A1 (enExample)
JP (2) JP7675648B2 (enExample)
KR (1) KR20210057130A (enExample)
CN (1) CN112955216A (enExample)
AU (2) AU2019340472A1 (enExample)
BR (1) BR112021004689A2 (enExample)
CA (1) CA3112473A1 (enExample)
TW (1) TWI834720B (enExample)
WO (1) WO2020053815A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110545850A (zh) * 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
CA3184998A1 (en) 2020-08-05 2022-02-10 Samuel WEISBROD Conjugates comprising reversible linkers and uses thereof
US20230372539A1 (en) * 2020-08-24 2023-11-23 The Trustees Of The University Of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
CN113430154A (zh) * 2021-05-21 2021-09-24 深圳市前海金卓生物技术有限公司 分泌glp-1的蛋白表达系统及其制备方法和应用
WO2024079739A1 (en) * 2022-10-14 2024-04-18 Bhami's Research Laboratory, Pvt. Ltd. Polypeptide formulations for oral delivery
JPWO2024101446A1 (enExample) * 2022-11-10 2024-05-16
IL323019A (en) * 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2012080836A2 (en) * 2010-12-13 2012-06-21 Marek Kwiatkowski Functionalized polymers

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US5830600A (en) 1996-05-24 1998-11-03 Sri International Nonflammable/self-extinguishing electrolytes for batteries
JPH10175987A (ja) 1996-12-13 1998-06-30 Nof Corp 重合性基含有有機リン酸エステル化合物およびその製造方法
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5922897A (en) 1998-05-29 1999-07-13 Xerox Corporation Surfactant processes
US20030165849A1 (en) 2000-11-28 2003-09-04 Biliang Zhang Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of RNA
US6320041B1 (en) 2001-04-13 2001-11-20 Trilink Biotechnologies, Inc. Pre-activated carbonyl linkers for the modification of oligonucleotides
US6743905B2 (en) 2001-04-16 2004-06-01 Applera Corporation Mobility-modified nucleobase polymers and methods of using same
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US20100240730A1 (en) 2002-02-20 2010-09-23 Merck Sharp And Dohme Corp. RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA)
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1594440B1 (en) 2003-02-14 2019-07-03 Quanta Biodesign, Ltd. The selective and specific preparation of discrete peg compounds
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US20070276139A1 (en) 2004-02-10 2007-11-29 Quanlai Song Substituted Pixyl Protecting Groups for Oligonucleotide Synthesis
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent
US8410047B2 (en) * 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US20060063147A1 (en) 2004-09-21 2006-03-23 Chernov Boris K Omega-amino-PEG-phosphoramidites and conjugates thereof
TW200612993A (en) 2004-10-08 2006-05-01 Alza Corp Lipopolymer conjugates
CN101291684A (zh) 2005-10-21 2008-10-22 阿维季尼克斯股份有限公司 甘醇化和糖基化的禽类来源的治疗性蛋白
WO2007055789A2 (en) 2005-10-31 2007-05-18 Neose Technologies, Inc. Expression of soluble therapeutic proteins
WO2007059912A1 (en) 2005-11-23 2007-05-31 Roche Diagnostics Gmbh Polynucleotide labelling reagent
JP5140824B2 (ja) 2006-04-19 2013-02-13 国立大学法人 東京大学 リゾホスファチジルスレオニンおよびその誘導体
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP5411703B2 (ja) 2006-11-09 2014-02-12 アルコン リサーチ， リミテッド 薬物送達のための水不溶性ポリマーマトリクス
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
EP2310440A4 (en) 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
US20110206633A1 (en) 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
WO2012019188A2 (en) 2010-08-06 2012-02-09 The Regents Of The University Of Colorado, A Body Corporate Methods and compositions for the inhibition of fructokinase
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
AU2013276219B2 (en) 2012-06-12 2018-03-08 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CN105813653B (zh) * 2013-12-19 2020-06-26 西雅图基因公司 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
CA2952834A1 (en) * 2014-06-20 2015-12-23 Abgenomics International Inc. Her2 antibody-drug conjugates
JP6369721B2 (ja) 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
SG10202011002WA (en) 2015-01-09 2020-12-30 Ascendis Pharma Growth Disorders As Cnp prodrugs
WO2016145536A1 (en) 2015-03-18 2016-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
ES2907651T3 (es) 2015-08-14 2022-04-25 Remegen Biosciences Inc Enlazadores covalentes en conjugados de anticuerpo-fármaco y métodos para obtener y usar los mismos
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
ES2985986T3 (es) 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
BR102017004833A2 (pt) 2017-03-10 2018-10-30 Leite Miguel produto bactericida/germicida/fungicida/esporocida extraído dos ácidos graxos a ser administrado via oral em animais de criação monogástricos e/ou ruminantes e método de obtenção
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
BR112020015071A2 (pt) 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
WO2012080836A2 (en) * 2010-12-13 2012-06-21 Marek Kwiatkowski Functionalized polymers

Also Published As

Publication number Publication date
TW202034947A (zh) 2020-10-01
US11357828B2 (en) 2022-06-14
WO2020053815A1 (en) 2020-03-19
US11957735B2 (en) 2024-04-16
CN112955216A (zh) 2021-06-11
JP2025023928A (ja) 2025-02-19
JP7675648B2 (ja) 2025-05-13
KR20210057130A (ko) 2021-05-20
US20200108124A1 (en) 2020-04-09
JP2021535920A (ja) 2021-12-23
CA3112473A1 (en) 2020-03-19
AU2019340472A1 (en) 2021-04-01
US20220118055A1 (en) 2022-04-21
AU2024227217A1 (en) 2024-10-31
BR112021004689A2 (pt) 2021-06-08
US20240181017A1 (en) 2024-06-06
EP3849660A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
US11957735B2 (en) Releasable GLP-1 conjugates
US11752211B2 (en) Fatty acids and their use in conjugation to biomolecules
US11896674B2 (en) SiRNA conjugate, preparation method therefor and use thereof
US10307434B2 (en) Nucleic acid prodrugs and methods of use thereof
CN105792852B (zh) 葡萄糖响应性的胰岛素缀合物
CN112004928A (zh) 寡核苷酸组合物及其使用方法
EP3603648B1 (en) Complex of nucleic acid medicine and multibranched lipid
WO2025043931A1 (zh) 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
CN120884604A (zh) 寡核苷酸组合物及其使用方法
AU2017326372B2 (en) Modified oligonucleotides and methods of use
TW201730200A (zh) 核酸複合體
JP2025524740A (ja) オリゴヌクレオチド送達増強剤、医薬組成物およびそれらを使用する方法
EP4650446A1 (en) Sirna for inhibiting expression of programmed cell death 1 ligand 1 gene, conjugate thereof, pharmaceutical composition thereof, and use thereof
WO2024217504A1 (zh) 缀合物及其应用和制备
WO2024230763A1 (zh) 一种新型的靶向化合物和核酸缀合物，及其用途
TW202516005A (zh) Ｓｉｒｎａ，含有ｓｉｒｎａ的綴合物，醫藥組成物及其用途
WO2025098440A1 (zh) 抑制PNPLA3表达的双链siRNA以及其缀合物
WO2024002045A1 (en) Oligonucleotide delivery agents, pharmaceutical compositions and methods using the same
WO2025002208A1 (zh) 一种核酸缀合物、制备方法及用途
HK40128800A (en) Oligonucleotide compositions and methods of use thereof
WO2025139811A1 (zh) 一种核酸缀合物、其制备方法和应用
HK40128806A (en) Oligonucleotide compositions and methods of use thereof
WO2026052075A1 (zh) 抑制CFB基因表达的siRNA及其用途
BR112016028884B1 (pt) Conjugado compreendendo uma biomolécula ligada a um ácido graxo, seu uso, mistura, combinação, composição farmacêutica, e composto